Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Ventripoint to debut new AI heart-scanning tech in Europe🚀
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
Comment by jopatcloon Oct 28, 2024 12:38pm
47 Views
Post# 36285240

RE:Ventripoint to debut new AI heart-scanning tech in Europe🚀

RE:Ventripoint to debut new AI heart-scanning tech in Europe🚀 Good timing for Ventripoint for Health. The BEST automation and analysis of the PLANET GEN3EHO Interesting https://cardiacwire.com/newsletter/americas-cvd-problem-bac-cac-screening/ “Magic pills, magic shots, and magic procedures will have no impact on this problem. Only a wholesale change in culture of health in USA will move the needle.” Johns Hopkins cardiologist Joseph Marine, MD. Cardiovascular Disease.America’s Growing CVD Problem It’s well known that heart disease is the U.S.’s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem.
Now That V4.0 Europe V4.0 ok & Canada FDA V4.0 and Sales at any time now Insiders know!On Ascend website https://ascendcv.com/ The BEST automation and analysis of the PLANET GEN3EHO The imaging community will likely propel this much more than any marketing company can. The Ollie Hinkle Foundation posted videos of their Take Heart 2024 conference on YouTube. In the first session Dr. Soriano of Seattle Children's Hospital provides a very nice overview of VMS+ and its benefits to patients and care providers.https://www.youtube.com/watch?app=desktop&v=Ucu6uGRMtEs Ollie Hinkle Heart Foundation Now 615 vues Take Heart 2024: Session 1 (Friday, October 4)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities